Chinese spies are posing as recruiters to target officials and journalists 
Genocide the Non Profit Industrial Complex and the Democratic Party 
Uncomfortable Undertones in Lee’s Sweep of South Korean Polls The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA) said in a statement on Saturday.
The drug regulator did not reveal the number of transactions.
Advertisement
Outlicensing agreements typically involve a company granting another firm the exclusive rights to further develop, manufacture and commercialise a drug once it has entered human clinical trials, in return for upfront payments, milestone fees and royalties on future sales.
“Chinese biotech firms have shown substantial technological advancements over the past few years and some of their innovative research has piqued the interest of international pharmaceutical big names,” said Meng Tianying, a senior executive at Shanghai-based consultancy Domo Medical. “It has become a new bright spot of the Chinese economy in line with the government’s efforts to encourage innovation.”
Advertisement
Innovative drugs – novel medicines targeting unmet medical needs, including new chemical entities and advanced biologics – were expected to grow at an annualised pace of 20 per cent between 2026 and 2030 in mainland China, before slowing to 8.8 per cent from 2030 to 2040, according to Chen Chen, head of China healthcare research at UBS.
Don't Miss:
-
Hong Kong issues amber rainstorm warning as storms follow record heat
-
Young South Koreans embrace ‘plogging’ to cope with climate anxiety
-
Son of James Handy’s girlfriend charged with murder of ‘Top Gun’ actor
-
Why North Korea’s Kim is doubling down on nuclear might as Xi visit looms
-
Does Pete Hegseth’s volte-face on China reflect an America in decline?